Merck Granted Seven Additional CRISPR Patents, Bringing Total to 20 Worldwide

Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75

▴

Patent offices in Europe, Israel, South Korea and U.K. issue seven additional grants for Merck's CRISPR genome-editing technology - Merck has 20 allowed CRISPR patents to date across nine different geographies

A leading science and technology company, today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing seven additional Merck patent application claims covering CRISPR gene-editing technology, bringing the number of patents to 20 worldwide.

"It is encouraging to see this important body of scientific work recognized with the grants of these latest CRISPR patents," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. "Our ambition is to continue growing our CRISPR intellectual property portfolio with technologies such as paired Cas9 nickases, for reducing off-target effects, and proxy-CRISPR, which offers researchers more experimental options to accelerate drug development and access to new therapies."

Details on Merck's latest CRISPR patent awards are as follows:

European Patent Office — Patent allowances for: These two newly allowed claim sets cover compositions that can be used forgene knock-in and gene knock-out. Israeli IP Office — Patent allowance for: Vectors for CRISPR integration. The newly allowed claims cover vector compositions to support CRISPR delivery and expression in eukaryotic cells, including viral delivery methods broadly used in both cancer research (lentivirus) and human therapeutic applications (adeno-associated virus, or AAV). proxy-CRISPR technology, which provides access to modify difficult-to-reach genomic regions, expanding CRISPR design options. This approach also allows a reduction in off-target effects. Engineered Ribonucleic Acid (RNA)-guided endonuclease and protein- RNA complexes. Paired Nickase technology, to reduce off-target effects. Paired nickases represent a significant step in increasing genome-editing safety. South Korean IP Office — Patent allowance for: Paired Nickase technology. U.K. (IP) Office — Patent allowance for: proxy-CRISPR technology.

Tags : #merckgrantedCRISPR #genome-editing #technology

Trending Now
	Healthcare Trends in 2026: What India's Doctors, Hospitals, and Patients Need to KnowJuly 18, 2026
	Monsoon Health Problems in India: Understanding the Risks, Symptoms, and PreventionJuly 18, 2026
	Fortis Escorts Faridabad Launches Faridabad’s First Comprehensive Lung Failure Clinic for Advanced Respiratory and Transplant CareJuly 17, 2026
	What Seemed Like Persistent Gas Turned Out To Be A 30-cm Rare Cancer Occupying Most Of Her AbdomenJuly 17, 2026
	Kidney Stone Prevention Initiative Unites More Than 8,200 Doctors Across India, Earns Asia Book of Records RecognitionJuly 17, 2026
	Moscow radiologists introduce AI tool for hip dysplasia diagnosisJuly 17, 2026
	Sharrp Ventures leads 100 CR investment in Naturis Cosmetics’ first institutional funding roundJuly 17, 2026
	Eugenix Challenges Hair Loss Stigma With Nationwide 'I Chose Transformation' Campaign Featuring Boney KapoorJuly 17, 2026
	How Artificial Intelligence is Reshaping Preventive Healthcare Through Earlier Detection and Smarter Clinical InsightsJuly 17, 2026
	Five Common Myths About Children's Urinary Problems That Parents Should Stop BelievingJuly 17, 2026
	Robotics in Surgery: How Robot-Assisted Procedures Are Transforming Healthcare in IndiaJuly 17, 2026
	Wearable Health Devices: How Smart Technology Is Changing Healthcare in IndiaJuly 17, 2026
	Sankara Eye Hospitals Successfully Hosts 20th Annual VISION 2020 India Conference, Celebrating 50 Years of the Sankara MovementJuly 16, 2026
	Manipal Hospital Bhubaneswar Successfully Treats Rare Brain Injury Caused by Post-Traumatic Workplace AccidentJuly 16, 2026
	Immuneel Therapeutics and Tata Memorial Centre Sign Strategic MoU to Advance Cell and Gene Therapy Research in India July 16, 2026
	Breast Cancer Early Warning Signs: What Every Woman in India Needs to KnowJuly 16, 2026
	HbA1c Test Explained: What It Measures, Normal Range, and Why It Matters for IndiansJuly 16, 2026
	Not Just Weight Loss: How Bariatric Surgery Improves Diabetes, PCOS, and Thyroid-Related Health ChallengesJuly 15, 2026
	Leiutis Pharmaceuticals announces CDSCO approval for Global-First Synthetic CBD Therapy for Mild to Moderate Anxiety DisordersJuly 15, 2026
	Dr Agarwals Institute of Optometry and SASTRA University Jointly Launch Optometry ProgrammeJuly 15, 2026